MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo

Lorna R. Fiedler, Kathryn Chapman, Min Xie, Evie Maifoshie, Micaela Jenkins, Pelin Arabacilar Golforoush, Mohamed Bellahcene, Michela Noseda, Dörte Faust, Ashley Jarvis, Gary Newton, Marta Abreu Paiva, Mutsuo Harada, Daniel J. Stuckey, Weihua Song, Josef Habib, Priyanka Narasimham, Rehan Aqil, Devika Sanmugalingam, Robert YanLorenzo Pavanello, Motoaki Sano, Sam C. Wang, Robert D. Sampson, Sunthar Kanayaganam, George E. Taffet, Lloyd H. Michael, Mark L. Entman, Tse Hua Tan, Sian E. Harding, Caroline M.R. Low, Catherine Tralau-Stewart, Trevor Perrior, Michael D. Schneider

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival. Using human iPSC-derived cardiomyocytes to enhance cardiac drug discovery, Fiedler et al. performed MAP4K4 target validation by gene silencing in this human model. MAP4K4 inhibitors augment human cardiomyocyte viability and function in 2D culture and 3D engineered heart tissue. An exemplar successfully reduces infarct size in proof-of-principle studies in mice.

Original languageEnglish
Pages (from-to)579-591.e12
JournalCell stem cell
Volume24
Issue number4
DOIs
Publication statusPublished - 2019 Apr 4
Externally publishedYes

Fingerprint

Cardiac Myocytes
Stem Cells
Induced Pluripotent Stem Cells
Drug Discovery
Gene Silencing
MAP Kinase Kinase Kinases
Reperfusion Injury
Cause of Death
Rodentia
Heart Diseases
Cell Survival
Oxidative Stress
Cell Death
Phosphotransferases
Calcium

Keywords

  • apoptosis
  • cardiac muscle
  • drug discovery
  • heart
  • signal transduction

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this

Fiedler, L. R., Chapman, K., Xie, M., Maifoshie, E., Jenkins, M., Golforoush, P. A., ... Schneider, M. D. (2019). MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo. Cell stem cell, 24(4), 579-591.e12. https://doi.org/10.1016/j.stem.2019.01.013

MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo. / Fiedler, Lorna R.; Chapman, Kathryn; Xie, Min; Maifoshie, Evie; Jenkins, Micaela; Golforoush, Pelin Arabacilar; Bellahcene, Mohamed; Noseda, Michela; Faust, Dörte; Jarvis, Ashley; Newton, Gary; Paiva, Marta Abreu; Harada, Mutsuo; Stuckey, Daniel J.; Song, Weihua; Habib, Josef; Narasimham, Priyanka; Aqil, Rehan; Sanmugalingam, Devika; Yan, Robert; Pavanello, Lorenzo; Sano, Motoaki; Wang, Sam C.; Sampson, Robert D.; Kanayaganam, Sunthar; Taffet, George E.; Michael, Lloyd H.; Entman, Mark L.; Tan, Tse Hua; Harding, Sian E.; Low, Caroline M.R.; Tralau-Stewart, Catherine; Perrior, Trevor; Schneider, Michael D.

In: Cell stem cell, Vol. 24, No. 4, 04.04.2019, p. 579-591.e12.

Research output: Contribution to journalArticle

Fiedler, LR, Chapman, K, Xie, M, Maifoshie, E, Jenkins, M, Golforoush, PA, Bellahcene, M, Noseda, M, Faust, D, Jarvis, A, Newton, G, Paiva, MA, Harada, M, Stuckey, DJ, Song, W, Habib, J, Narasimham, P, Aqil, R, Sanmugalingam, D, Yan, R, Pavanello, L, Sano, M, Wang, SC, Sampson, RD, Kanayaganam, S, Taffet, GE, Michael, LH, Entman, ML, Tan, TH, Harding, SE, Low, CMR, Tralau-Stewart, C, Perrior, T & Schneider, MD 2019, 'MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo', Cell stem cell, vol. 24, no. 4, pp. 579-591.e12. https://doi.org/10.1016/j.stem.2019.01.013
Fiedler, Lorna R. ; Chapman, Kathryn ; Xie, Min ; Maifoshie, Evie ; Jenkins, Micaela ; Golforoush, Pelin Arabacilar ; Bellahcene, Mohamed ; Noseda, Michela ; Faust, Dörte ; Jarvis, Ashley ; Newton, Gary ; Paiva, Marta Abreu ; Harada, Mutsuo ; Stuckey, Daniel J. ; Song, Weihua ; Habib, Josef ; Narasimham, Priyanka ; Aqil, Rehan ; Sanmugalingam, Devika ; Yan, Robert ; Pavanello, Lorenzo ; Sano, Motoaki ; Wang, Sam C. ; Sampson, Robert D. ; Kanayaganam, Sunthar ; Taffet, George E. ; Michael, Lloyd H. ; Entman, Mark L. ; Tan, Tse Hua ; Harding, Sian E. ; Low, Caroline M.R. ; Tralau-Stewart, Catherine ; Perrior, Trevor ; Schneider, Michael D. / MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo. In: Cell stem cell. 2019 ; Vol. 24, No. 4. pp. 579-591.e12.
@article{35f2fe66ab874f3993db172d8aaf1232,
title = "MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo",
abstract = "Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50{\%}. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival. Using human iPSC-derived cardiomyocytes to enhance cardiac drug discovery, Fiedler et al. performed MAP4K4 target validation by gene silencing in this human model. MAP4K4 inhibitors augment human cardiomyocyte viability and function in 2D culture and 3D engineered heart tissue. An exemplar successfully reduces infarct size in proof-of-principle studies in mice.",
keywords = "apoptosis, cardiac muscle, drug discovery, heart, signal transduction",
author = "Fiedler, {Lorna R.} and Kathryn Chapman and Min Xie and Evie Maifoshie and Micaela Jenkins and Golforoush, {Pelin Arabacilar} and Mohamed Bellahcene and Michela Noseda and D{\"o}rte Faust and Ashley Jarvis and Gary Newton and Paiva, {Marta Abreu} and Mutsuo Harada and Stuckey, {Daniel J.} and Weihua Song and Josef Habib and Priyanka Narasimham and Rehan Aqil and Devika Sanmugalingam and Robert Yan and Lorenzo Pavanello and Motoaki Sano and Wang, {Sam C.} and Sampson, {Robert D.} and Sunthar Kanayaganam and Taffet, {George E.} and Michael, {Lloyd H.} and Entman, {Mark L.} and Tan, {Tse Hua} and Harding, {Sian E.} and Low, {Caroline M.R.} and Catherine Tralau-Stewart and Trevor Perrior and Schneider, {Michael D.}",
year = "2019",
month = "4",
day = "4",
doi = "10.1016/j.stem.2019.01.013",
language = "English",
volume = "24",
pages = "579--591.e12",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo

AU - Fiedler, Lorna R.

AU - Chapman, Kathryn

AU - Xie, Min

AU - Maifoshie, Evie

AU - Jenkins, Micaela

AU - Golforoush, Pelin Arabacilar

AU - Bellahcene, Mohamed

AU - Noseda, Michela

AU - Faust, Dörte

AU - Jarvis, Ashley

AU - Newton, Gary

AU - Paiva, Marta Abreu

AU - Harada, Mutsuo

AU - Stuckey, Daniel J.

AU - Song, Weihua

AU - Habib, Josef

AU - Narasimham, Priyanka

AU - Aqil, Rehan

AU - Sanmugalingam, Devika

AU - Yan, Robert

AU - Pavanello, Lorenzo

AU - Sano, Motoaki

AU - Wang, Sam C.

AU - Sampson, Robert D.

AU - Kanayaganam, Sunthar

AU - Taffet, George E.

AU - Michael, Lloyd H.

AU - Entman, Mark L.

AU - Tan, Tse Hua

AU - Harding, Sian E.

AU - Low, Caroline M.R.

AU - Tralau-Stewart, Catherine

AU - Perrior, Trevor

AU - Schneider, Michael D.

PY - 2019/4/4

Y1 - 2019/4/4

N2 - Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival. Using human iPSC-derived cardiomyocytes to enhance cardiac drug discovery, Fiedler et al. performed MAP4K4 target validation by gene silencing in this human model. MAP4K4 inhibitors augment human cardiomyocyte viability and function in 2D culture and 3D engineered heart tissue. An exemplar successfully reduces infarct size in proof-of-principle studies in mice.

AB - Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival. Using human iPSC-derived cardiomyocytes to enhance cardiac drug discovery, Fiedler et al. performed MAP4K4 target validation by gene silencing in this human model. MAP4K4 inhibitors augment human cardiomyocyte viability and function in 2D culture and 3D engineered heart tissue. An exemplar successfully reduces infarct size in proof-of-principle studies in mice.

KW - apoptosis

KW - cardiac muscle

KW - drug discovery

KW - heart

KW - signal transduction

UR - http://www.scopus.com/inward/record.url?scp=85063026492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063026492&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2019.01.013

DO - 10.1016/j.stem.2019.01.013

M3 - Article

C2 - 30853557

AN - SCOPUS:85063026492

VL - 24

SP - 579-591.e12

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 4

ER -